Marker Therapeutics shares are trading higher after the FDA on Thursday announced clearance to the company's Investigational New Drug application for MT-601 for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma.
Marker Therapeutics shares are trading higher after the FDA on Thursday announced clearance to the company's Investigational New Drug application for MT-601 for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.